POSA411 Real World Outcomes of First Line Pembrolizumab Monotherapy for Advanced PD-L1 Positive Non-Small Cell Lung Cancer

Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.1237
https://www.valueinhealthjournal.com/article/S1098-3015(21)03032-1/fulltext
Section Title :
Section Order : 10776
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)03032-1&doi=10.1016/j.jval.2021.11.1237
HEOR Topics :
Tags :
Regions :